Pricing
Pricing built around your compound portfolio, not user count.
Two tiers. Configure once. No per-seat surprises.
Tiers
Two tiers for two kinds of PV obligation
Portfolio Monitor
For PV teams managing a defined compound portfolio with US post-market monitoring obligations. FAERS signal detection with weekly MedDRA-coded signal digest reports. EudraVigilance and VigiBase coverage available on Enterprise Safety tier.
- FAERS signal monitoring (US)
- Multi-drug DDI detection for portfolio compounds
- Weekly signal digest reports
- MedDRA-coded signal output
- Audit log export
- Email + async support
Enterprise Safety
For PV departments monitoring broad compound portfolios across FDA, EMA, and PMDA jurisdictions. Includes multi-region ICSR surveillance, real-time signal alerts, PSUR/PBRER data compilation, and a dedicated PV science contact who knows your portfolio.
- Everything in Portfolio Monitor
- EudraVigilance + VigiBase coverage
- Real-time signal alerts (not weekly)
- ICSR processing automation
- PSUR/PBRER data compilation
- Safety system API integration
- Dedicated PV science support
- Custom compound prioritization
Pricing Rationale
Why we price this way
PV monitoring value is tied to compound risk exposure, not how many scientists access the dashboard. A portfolio with 10 cardiovascular compounds has 10 sets of post-market monitoring obligations — the number of scientists reviewing signal output is secondary.
We price per portfolio so your cost scales with your regulatory obligation, not your team size. For a mid-size specialty pharma company managing 8-12 active compounds, the math is straightforward: $24,000/year for signal detection that adds 91 days of early warning.
Enterprise Safety uses custom pricing because large portfolio monitoring scope, multi-region regulatory coverage, and dedicated PV science support don't fit a fixed formula. We size Enterprise contracts around the actual regulatory surface area.
FAQ
Pricing questions
One compound = one INN (International Nonproprietary Name / generic name), inclusive of all formulations, routes, and dosage strengths of that active ingredient. For example, "atorvastatin" covers immediate-release tablets, extended-release formulations, and all dose strengths. Combination products count by number of active ingredients — a fixed-dose combination of two INNs counts as two compounds.
Yes. Additional compounds beyond the Portfolio Monitor limit of 12 are pro-rated at the monthly equivalent rate for the remaining contract term. There's no penalty for portfolio changes — drug safety obligations are dynamic and your monitoring contract should reflect that. Enterprise Safety includes unlimited compounds.
Yes. TrialVyx ingests the full historical FAERS corpus at onboarding — reports since 1990 for FDA FAERS. Your first signal analysis runs across the complete historical record, not just forward-looking from your start date. This means the retrospective baseline for your compound portfolio is available immediately at launch.
TrialVyx processes only de-identified public regulatory data — FAERS, EudraVigilance, and VigiBase are all de-identified at source by the regulatory agencies. We do not receive, store, or process any proprietary patient-level data from your systems. Your compound portfolio list (the drugs we monitor for you) is stored under access controls with encryption at rest and in transit. Full details on our security page.
Start with your compound portfolio list.
TrialVyx is in early access. We work directly with your PV team to configure N-drug signal detection for your specific INNs and therapeutic area before the contract is signed — so you know what you're getting.
[email protected] | +1 (617) 924-6439